The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AFMD | -100% | -100% | -92.12% | -100% |
| S&P | +15.06% | +95.03% | +14.29% | +239% |
Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager molecules, which use patient's immune cells to destroy tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
The clinical-stage biotech focuses on immuno-oncology therapies.
An analyst's downgrade brings out the bears for the European cancer treatment developer.
| Q3 2024 | YOY Change | |
|---|---|---|
| Revenue | $0.17M | 0.0% |
| Market Cap | $51.16M | 0.0% |
| Market Cap / Employee | $0.66M | 0.0% |
| Employees | 78 | 0.0% |
| Net Income | -$16.63M | 0.0% |
| EBITDA | -$15.23M | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2024 | YOY Change | |
|---|---|---|
| Net Cash | $8.26M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Long Term Debt | $6.68M | 0.0% |
| Short Term Debt | $7.70M | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Return On Assets | -88.07% | 0.0% |
| Return On Invested Capital | -74.43% | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$13.13M | 0.0% |
| Operating Free Cash Flow | -$13.12M | 0.0% |
| Metric | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.15 | 1.24 | 1.89 | 1.71 | - |
| Price to Sales | 10.50 | 18.83 | 28.63 | 57.04 | - |
| Price to Tangible Book Value | 11.54 | 1.25 | 1.89 | 1.71 | - |
| Enterprise Value to EBITDA | -1.38 | -2.36 | -3.80 | -2.73 | - |
| Return on Equity | -100.9% | -112.4% | -123.5% | -151.5% | - |
| Total Debt | $21.38M | $17.36M | $15.56M | $14.38M | - |
AFMD earnings call for the period ending September 30, 2021.
AFMD earnings call for the period ending June 30, 2021.
AFMD earnings call for the period ending September 30, 2020.
AFMD earnings call for the period ending June 30, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
